NCT04115761 is a Phase 2 clinical trial of autologous dendritic cells in GBM, sponsored by Ever Supreme Bio Technology Co., Ltd..

Who is sponsoring NCT04115761?

NCT04115761 is sponsored by Ever Supreme Bio Technology Co., Ltd..

What drugs are being tested in NCT04115761?

Interventions in NCT04115761: autologous dendritic cells.

Is NCT04115761 still recruiting?

NCT04115761 is currently recruiting now. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT04115761

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluate the Efficacy and Safety of ADCV01 As an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients

Recruiting now Phase 2 Last updated 19 September 2024

What this trial tests

Phase 2 trial testing autologous dendritic cells in GBM in 24 participants. Currently enrolling.

Timeline

6 June 2019

Primary endpoint
30 December 2026

30 December 2026

Quick facts

Lead sponsor	Ever Supreme Bio Technology Co., Ltd.
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	6 June 2019
Primary completion	30 December 2026
Estimated completion	30 December 2026
Sites	3 locations across Taiwan

Drugs / interventions tested

autologous dendritic cells — full drug profile →

Conditions studied

GBM — all drugs for GBM →

Sponsor

Ever Supreme Bio Technology Co., Ltd. — full company profile →

Who can join

Adults 20 to 75, any sex, with GBM. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed with open-label and randomized parallel group to evaluate the efficacy and safety of autologous dendritic cell vaccination (ADCV01) as an add-on treatment for primary glioblastoma multiforme

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Lin H, Liu C, Hu A, Zhang D, et al · · 2024 · cited 232× · PMID 38720342 · DOI 10.1186/s13045-024-01544-7
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.
Laureano RS, Sprooten J, Vanmeerbeerk I, Borras DM, et al · · 2022 · cited 101× · PMID 35800158 · DOI 10.1080/2162402x.2022.2096363
Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
Pearson JRD, Cuzzubbo S, McArthur S, Durrant LG, et al · · 2020 · cited 92× · PMID 33178210 · DOI 10.3389/fimmu.2020.582106
Glioblastoma vaccines: past, present, and opportunities.
Xiong Z, Raphael I, Olin M, Okada H, et al · · 2024 · cited 57× · PMID 38183840 · DOI 10.1016/j.ebiom.2023.104963
Pathogenetic Features and Current Management of Glioblastoma.
Nguyen HM, Guz-Montgomery K, Lowe DB, Saha D. · · 2021 · cited 42× · PMID 33670551 · DOI 10.3390/cancers13040856
Clinical implication of cellular vaccine in glioma: current advances and future prospects.
Yan Y, Zeng S, Gong Z, Xu Z. · · 2020 · cited 42× · PMID 33228738 · DOI 10.1186/s13046-020-01778-6
Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged.
Van Gool SW, Makalowski J, Fiore S, Sprenger T, et al · · 2020 · cited 28× · PMID 33374196 · DOI 10.3390/cancers13010032
Trial watch: anticancer vaccination with dendritic cells.
Borges F, Laureano RS, Vanmeerbeek I, Sprooten J, et al · · 2024 · cited 18× · PMID 39398476 · DOI 10.1080/2162402x.2024.2412876

Verify or expand the search:

Other recruiting trials for GBM

Currently open trials in the same condition.

NCT05902169 — Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM · Phase 3 · active not recruiting
NCT05879367 — Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma · Phase 1 · recruiting
NCT05954858 — Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma · NA · recruiting
NCT05933265 — Study of LP-184 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06018363 — Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection · Phase 1, PHASE2 · recruiting

Other Ever Supreme Bio Technology Co., Ltd. trials

Trials by the same sponsor.

NCT06150885 — A Safety and Efficacy Study of Allogeneic CAR Gamma-Delta T Cells in Subjects with Relapsed/Refractory Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06147986 — Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells As an Add-On Treatment for Acute ST · Phase 2 · recruiting
NCT05532943 — Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis · Phase 1, PHASE2 · recruiting
NCT04434768 — Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke · Phase 1 · active not recruiting
NCT05501418 — Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19 · Phase 1, PHASE2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04115761 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ever Supreme Bio Technology Co., Ltd.
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04115761.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing